Patents Issued in September 12, 2017
  • Patent number: 9758522
    Abstract: Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L1 represents a linker; and RH represents a hydrophobic group. An example of a compound of Formula (I) is a compound of Formula (II): Also provided are pharmaceutical compositions comprising a compound of Formula (I) or (II) and methods of using such compounds for treating proliferative diseases.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 12, 2017
    Assignees: Dana-Farber Cancer Institute, Inc., Yale University
    Inventors: Nathanael Gray, Ting Xie, Sang Min Lim, Pasi A. Janne, Craig M. Crews
  • Patent number: 9758523
    Abstract: The present invention is directed to [1,2,4]triazolo[4,3-a]pyridine and [1,2,4]triazolo[4,3-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: September 12, 2017
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Patent number: 9758524
    Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to Formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to Formula (I) in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: September 12, 2017
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Tjeerd A. Barf, Christiaan Gerardus Johannes Maria Jans, Adrianus Petrus Antonius de Man, Arthur A. Oubrie, Hans C. A. Raaijmakers, Johannes Bernardus Maria Rewinkel, Jan Gerard Sterrenburg, Jacobus C. H. M. Wijkmans
  • Patent number: 9758525
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: September 12, 2017
    Assignee: Aptinyx Inc.
    Inventors: John A. Lowe, III, M. Amin Khan
  • Patent number: 9758526
    Abstract: An object to be achieved by the present invention is to provide a novel compound having EGFR inhibitory effects and cell growth inhibitory effects, as well as a medication useful for the prevention and/or treatment of cancer based on the EGFR inhibitory effects. The present invention provides a compound represented by Formula (I) below, or a salt thereof.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: September 12, 2017
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Takao Uno, Katsumasa Nonoshita, Tadashi Shimamura
  • Patent number: 9758527
    Abstract: The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: September 12, 2017
    Assignee: HYUNDAI PHARM CO., LTD.
    Inventors: Jin Yang, Jinwoong Kim, Han Kyu Lee, Jae Hyun Kim, Chang Mo Son, Kyu Hwan Lee, Jeongun Hwang, Hyung-Ho Choi, Daehoon Kim, Jaekeol Rhee
  • Patent number: 9758528
    Abstract: The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrimidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethyl aminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1?-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: September 12, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Koichiro Fukuoka, Kazuhiro Miwa, Tsuyoshi Sasaki, Fumiya Komura
  • Patent number: 9758529
    Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Ring B, A1, A2, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: September 12, 2017
    Assignees: Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
    Inventors: Milan Chytil, Sharon Engel, Taleen G. Hanania, Vadim Alexandrov, Emer Leahy
  • Patent number: 9758530
    Abstract: The invention provides novel compounds having the general formula: wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as or pharmaceutically acceptable salts, or tautomerism isomers, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: September 12, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Lei Guo, Taishan Hu, Yimin Hu, Buelent Kocer, Buyu Kou, Gangqin Li, Xianfeng Lin, Haixia Liu, Hong Shen, Houguang Shi, Guolong Wu, Zhisen Zhang, Mingwei Zhou, Wei Zhu
  • Patent number: 9758531
    Abstract: Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 12, 2017
    Assignee: Samumed, LLC
    Inventors: Sunil Kumar KC, David Mark Wallace, Jianguo Cao, Chandramouli Chiruta, John Hood
  • Patent number: 9758532
    Abstract: Compositions and methods comprising metal organic frameworks (MOFs) and related uses are generally provided. In some embodiments, an MOF comprises a plurality of metal ions, each coordinated with at least one ligand comprising at least two unsaturated N-heterocyclic aromatic groups arranged about an organic core. In some embodiments, an MOF may be used in applications related to water adsorption.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: September 12, 2017
    Assignee: Massacusetts Institute of Technology
    Inventors: Mircea Dinca, Casey R. Wade
  • Patent number: 9758533
    Abstract: A reaction method comprising combining a carbonyl-substituted arylboronic acid or ester and an ?-effect amine in aqueous solution at a temperature between about ?5 C to 55 C, and a pH between 2 and 8 to produce an adduct. A process is also provided comprising: contacting a composition having a boron atom bonded to a sp2 hybridized carbon, the boron having at least one labile substituent, conjugated with a cis-carbonyl, with an ?-effect amine, in an aqueous medium for a time sufficient to form an adduct, which may proceed to further products.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: September 12, 2017
    Assignee: The Research Foundation for The State University of New York
    Inventors: Susan Bane Tuttle, Ozlem Dilek, Kamalika Mukherjee
  • Patent number: 9758534
    Abstract: Organoaminosilanes, such as without limitation di-iso-propylaminosilane (DIPAS), are precursors for the deposition of silicon containing films such as silicon-oxide and silicon-nitride films. Described herein are methods to make organoaminosilane compounds, or other compounds such as organoaminodisilanes and organoaminocarbosilanes, via the catalytic hydrosilylation of an imine by a silicon source comprising a hydridosilane.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: September 12, 2017
    Assignee: VERSUM MATERIALS US, LLC
    Inventors: Manchao Xiao, Matthew R. MacDonald, Richard Ho, Xinjian Lei
  • Patent number: 9758535
    Abstract: System, including methods and compositions, for making and using emulsions that include a silicone oil and a silicone surfactant. The emulsions may include aqueous droplets disposed in a continuous phase that includes a silicone oil and a silicone surfactant. The aqueous droplets may contain an analyte, optionally at partial occupancy, and/or a luminescent (e.g., photoluminescent) reporter. An assay of the analyte may be performed with the droplets. In some cases, signals may be detected from the droplets, and a characteristic of the analyte, such as an analyte level or activity, may be determined based on the signals.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: September 12, 2017
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Erin R. Chia, Amy L. Hiddessen, Benjamin J. Hindson, Adam Lowe, Chunxiao Han
  • Patent number: 9758536
    Abstract: The present invention concerns phospholipid compositions having a relatively high concentration of compounds of the following structure (I): wherein at least one of R1 and R2 is palmitoleoyl, myristoleoyl or lauroleoyl and methods for their preparation. The present invention also concerns the use of these phospholipid compositions to treat a variety of disorders by administering the composition to a patient in need thereof.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: September 12, 2017
    Assignee: Omega Protein Corporation
    Inventors: Ernesto Hernandez, Marina Rusli, Mark Griffin
  • Patent number: 9758537
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: September 12, 2017
    Assignee: Achillion Pharmaceuticals
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Xiangzhu Wang, Dawei Chen, Akihiro Hashimoto, Venkat Rao Gadhachanda, Godwin Pais, Qiuping Wang, Atul Agarwal, Milind Deshpande
  • Patent number: 9758538
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1-R11, m, n, and p are defined herein. The novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: September 12, 2017
    Assignee: PFIZER INC.
    Inventors: Ping Chen, Hengmiao Cheng, Gary Michael Gallego, Mehran Jalaie, John Charles Kath, Suvi Tuula Marjukka Orr, Mason Alan Pairish
  • Patent number: 9758539
    Abstract: Compounds having the following structure (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of R1, R2 or R3 is —P(?O)(OH)2, and the other two of R1, R2 and R3 are each H, are provided. Pharmaceutical compositions comprising the compounds, and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 12, 2017
    Assignee: Tolero Pharmaceuticals, Inc.
    Inventors: Adam Siddiqui-Jain, David J. Bearss
  • Patent number: 9758540
    Abstract: Disclosed herein are catalyst compositions containing bicyclic bridged metallocene compounds. These catalyst compositions can be used for the polymerization of olefins. For example, ethylene polymers produced using these catalyst compositions can be characterized by low molecular weights and high melt flow rates, and can be produced without the addition of hydrogen.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: September 12, 2017
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: Jeremy M. Praetorius, Qing Yang, Connor D. Boxell, Tony R. Crain
  • Patent number: 9758541
    Abstract: The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof, a stereoisomer or a mixture of stereoisomers in any ratio, or a water-soluble derivative, as well as to methods for preparing same and to the use thereof, in particular in the treatment of cancer.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: September 12, 2017
    Assignee: PARIS SCIENCES ET LETTRES—QUARTIER LATIN
    Inventors: Gerard Jaouen, Pascal Pigeon, Siden Top
  • Patent number: 9758542
    Abstract: A coating of a random copolymer of acrylamide and a second monomer, e.g. glycidoxylmethacrylate, for a silica surface is described. The coating is applied to chromatographic support structures having silica based surfaces. The coating is functionalized to produce protein chromatography matrices that are particularly useful for extracting trace amounts of biomarker molecules from biological samples.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: September 12, 2017
    Assignee: Purdue Research Foundation
    Inventors: Mary J. Wirth, Yimin Hua, Zhaorui Zhang
  • Patent number: 9758543
    Abstract: An alkenyl glycoside is prepared by reacting a metathesis-derived unsaturated fatty alcohol containing 10 to 30 carbon atoms with either (1) a reducible monosaccharide or composition hydrolyzable to a reducible monosaccharide, or (2) a hydrocarbyl glycoside produced by reacting an alcohol containing up to 6 carbon atoms with a reducible monosaccharide or composition hydrolyzable to a reducible monosaccharide. Each of these reactions is performed in the presence of an acid catalyst and under conditions sufficient to form the alkenyl glycoside or hydrocarbyl glycoside. The preferred alkenyl glycosides are 9-decen-1-yl glycoside; 9-dodecen-1-yl glycoside; 9-tridecen-1-yl glycoside; 9-pentadecen-1-yl glycoside; 9-octadecen-yl glycoside; or 9-octadecen-1,18-diyl glycoside.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: September 12, 2017
    Assignee: Elevance Renewable Sciences, Inc.
    Inventors: Ryan A. Littich, Jonathan Brekan, Timothy Montavon
  • Patent number: 9758544
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: September 12, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, David Bernard Smith, Guangyi Wang, Natalia Dyatkina
  • Patent number: 9758545
    Abstract: The present invention relates to a scaffolded sensor with a container comprising a drug for triggering drug release, wherein the scaffold is intrinsically conformationally metastable and a method to its manufacture.
    Type: Grant
    Filed: October 24, 2011
    Date of Patent: September 12, 2017
    Assignee: UNIVERSITÉ DE FRIBOURG
    Inventors: Katharina Fromm, Christian Bochet
  • Patent number: 9758546
    Abstract: Provided herein are methods for the synthesis of oligomeric compounds wherein removal of the 5?-terminal trityl group is performed at reduced temperature and lower pH relative to standard methods. In certain embodiments, the present methods provide detritylated oligomeric compounds having a reduced percentage of depurination relative to the same detritylated oligomeric compounds prepared using standard methods. In certain embodiments, the present methods provide detritylated oligomeric compounds with increased purity relative to the same detritylated oligomeric compounds prepared using standard methods. In certain embodiments, the present method provide an increased rate of detritylation compared to standard methods.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: September 12, 2017
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventor: Dana Chreng
  • Patent number: 9758547
    Abstract: Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: September 12, 2017
    Assignee: 3M Innovative Properties Company
    Inventors: Jerald K. Rasmussen, Kannan Seshadri, Robert T. Fitzsimons, Jr., James I. Hembre, Catherine A. Bothof, Erin A. Satterwhite, George W. Griesgraber, Yi He, Louis C. Haddad
  • Patent number: 9758548
    Abstract: A method of treating a bacterial infection in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of a peptide being between 3 and 5 amino acids, wherein at least one amino acid of the 3 and 5 amino acids is selected from the group consisting of tryptophan, cysteine, proline and methionine.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: September 12, 2017
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Noam Adir, Sharon Navon, Tali Swartzmann
  • Patent number: 9758549
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: September 12, 2017
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
  • Patent number: 9758550
    Abstract: The present invention relates to a cobalamin acquisition protein, compositions containing the cobalamin acquisition protein, and the use of such compositions.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: September 12, 2017
    Assignee: Woods Hole Oceanographic Institution
    Inventors: Makoto Saito, Erin M. Bertrand
  • Patent number: 9758551
    Abstract: Nucleic acids encoding a chimeric or fusion polypeptide which polypeptide comprises a first domain comprising a translocation polypeptide; and a second domain comprising at least one antigenic peptide are disclosed. The preferred translocation polypeptide is a bacterial toxin translocation polypeptide, such as domain II of Pseudomonas aeruginosa exotoxin A (ETA(dII)). Such nucleic acids, expression vectors thereof, and cells expressing these vectors are used as vaccine compositions in a method for enhancing an antigen specific immune response, a method of increasing the numbers of CD8+ CTLs specific for a selected desired antigen in a subject, or a method of inhibiting the growth of a tumor in a subject.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: September 12, 2017
    Assignee: The Johns Hopkins University
    Inventors: Tzyy-Choou Wu, Chien-Fu Hung
  • Patent number: 9758552
    Abstract: A ligand recombinant protein inhibiting HB-EGF (Heparin-Binding Epidermal Growth Factor like), from the R domain of diphtheria toxin, which can be used for the treatment and diagnosis of diseases involving the activation of the HB-EGF/EGFR pathway.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: September 12, 2017
    Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
    Inventors: Daniel Gillet, Benoit Villiers, Sylvain Pichard, Bernard Maillere, Alain Sanson
  • Patent number: 9758553
    Abstract: Lower eukaryotic host cells have been engineered to produce glycoprotein having at least one terminal ?-galactosyl epitope. The glycoproteins are useful for the production of highly antigenic glycoprotein compositions with advantages for the production of vaccines.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: September 12, 2017
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Natarajan Sethuraman, Robert C. Davidson, Terrance A. Stadheim, Stefan Wildt
  • Patent number: 9758554
    Abstract: The present disclosure relates to a collection of novel muteins derived from human ?1m (or a1m) polypeptide or a functional homolog thereof. The disclosure further refers to a ?1m mutein capable of specifically binding to one or more targets other than a target to which wild-type ?1m binds. The disclosure also relates to a method for producing such collection of muteins and a method for isolating a mutein capable of binding one or more such non-natural targets of wild-type ?1m polypeptide. These aspects are made possible due to, e.g, the structural elucidation of ?1m disclosed herein by the present inventors, an appreciation of ligand-binding sights thereof and, hence, an understanding of which amino acid positions are most suitable for mutagenesis for re-engineering specificity and affinity for any given target while maintaining the secondary and/or tertiary structure of a1m.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: September 12, 2017
    Assignee: TECHNISCHE UNIVERSITAET MUENCHEN
    Inventors: Arne Skerra, Winfried Meining, Evelyn Eggenstein
  • Patent number: 9758555
    Abstract: The present invention relates to methods for treating and/or preventing tumors and/or promoting apoptosis in a neoplastic cell comprising contacting the neoplastic cell with an cell-penetrating dominant-negative ATF5 (“CP-d/n-ATF5”), wherein the CP-d/n-ATF5 is capable of inhibiting ATF5 function and/or activity.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 12, 2017
    Assignees: The Trustees of Columbia University in the City of New York, The Regents of the University of California
    Inventors: Lloyd A. Greene, James Angelastro
  • Patent number: 9758556
    Abstract: The present invention relates to methods for treating and/or preventing tumors and/or promoting apoptosis in a neoplastic cell comprising contacting the neoplastic cell with an cell-penetrating dominant-negative ATF5 (“CP-d/n-ATF5”), wherein the CP-d/n-ATF5 is capable of inhibiting ATF5 function and/or activity.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 12, 2017
    Assignees: The Trustees of Columbia University in the City of New York, The Regents of the University of California
    Inventors: Lloyd A. Greene, James Angelastro
  • Patent number: 9758557
    Abstract: Isolated C1q peptides, fusion proteins and compositions comprising such and fusion proteins comprising are provided. Isolated fusion proteins comprising X4WX5YX6 as defined herein and compositions comprising such are also provided. Methods of treating autoimmune disorders are provided.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: September 12, 2017
    Assignee: The Feinstein Institute for Medical Research
    Inventor: Betty A. Diamond
  • Patent number: 9758558
    Abstract: A biodegradable hydrogel has been made based on high concentrations of whey protein isolate (WPI). WPI gels of different compositions were fabricated by thermally inducing gelation of high-concentration suspensions of protein, and characterized for compressive strength and modulus, hydration swelling and drying properties, mechanical behavior change due to polysaccharide additives, and intrinsic pore network structure. The gels were shown to be compatible with bone cells and could be used as bone tissue scaffolds. In addition, WPI fibers were produced by electrospinning. Several additives could be incorporated into the WPI gels, including structural additives, growth factors, amino acids, etc. The WPI hydrogels can be made with glycerol to increase flexibility and stability.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: September 12, 2017
    Assignee: Board of Supervisors of Louisiana State University And Agriculture and Mechanical College
    Inventors: James E. Henry, Mia Dvora
  • Patent number: 9758559
    Abstract: The present invention relates to short peptides based on the amino acids sequence of the N-terminal domain of the human mitochondrial protein voltage-dependent anion channel 1 (VDAC) and to peptide conjugates having a cell permeability enhancing moiety. The peptides, peptide conjugates and pharmaceutical compositions containing them are useful for treating diseases characterized by cell hyperproliferation or resistance to cell death and in particular, cancer.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: September 12, 2017
    Assignees: B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University, The National Institute for Biotechnology in the Negev Ltd.
    Inventor: Varda Shoshan-Barmatz
  • Patent number: 9758560
    Abstract: The invention relates to a derivative of a GLP-1 peptide, which peptide has two Lys residues, namely a first and a second Lys residue, and a maximum of eight amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second Lys residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 15: HOOC—(CH2)x-CO—*, and Chem. 16: HOOC—C6H4-O—(CH2)y-CO—*, in which x is an integer in the range of 10-16, and y is an integer in the range of 8-12; and the linker comprises a first linker element *—NH—CH(CH2OH)—CO—*. A preferred linker is g Glu-Ser-Ser-Gly-Ser-Ser-Gly (SEQ ID NO: 2). The derivative of the invention has a very good potency, and a very good binding to the GLP-1 receptor. The invention also relates to the pharmaceutical use of the derivative, for example in the treatment and/or prevention of all forms of diabetes and related diseases.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: September 12, 2017
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Paw Bloch, Patrick William Garibay
  • Patent number: 9758561
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: September 12, 2017
    Assignee: SANOFI
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Dieter Kadereit
  • Patent number: 9758562
    Abstract: Provided herein are peptides and variant peptides that exhibit enhanced activity at the GLP-1 receptor, as compared to native glucagon.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: September 12, 2017
    Assignee: Indiana University and Technology Corporation
    Inventors: Richard D. DiMarchi, David L. Smiley
  • Patent number: 9758563
    Abstract: An insulin analog comprises a B-chain polypeptide incorporating a chlorinated phenylalanine. The chlorinated phenylalanine may be located at position B24. The chlorinated phenylalanine may be para-monochloro-phenylalanine. The analog may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analog. The chlorinated insulin analogs retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analog or a physiologically acceptable salt thereof to a patient. Chlorine substitution-based stabilization of insulin may reduce fibrillation and thereby enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: September 12, 2017
    Assignee: Case Western Reserve University
    Inventor: Michael Weiss
  • Patent number: 9758564
    Abstract: Provided are an acid-resistant yeast cell with genetic modification and reduced Fps1 activity compared to that of a parent cell without the genetic modification; and a method of producing lactate by using the yeast cell.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: September 12, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Juyoung Lee, Hyunyoung Shin, Changduk Kang, Seunghyun Lee, Kwangmyung Cho
  • Patent number: 9758565
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: September 12, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert James Peach, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Patent number: 9758566
    Abstract: This invention relates to recombinant CTLA-4 proteins, e.g., soluble CTLA-4 or CTLA-4 fusion toxins, and methods for making and using them.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: September 12, 2017
    Assignee: The General Hospital Corporation
    Inventors: Zhirui Wang, David H. Sachs, Christene A. Huang
  • Patent number: 9758567
    Abstract: The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: September 12, 2017
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Herbert Y. Lin, Jodie Babitt, Clifford J. Woolf, Tarek A. Samad
  • Patent number: 9758568
    Abstract: The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: September 12, 2017
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Artur Mitterer
  • Patent number: 9758569
    Abstract: Novel collagen mimics are disclosed with a tripeptide unit having the formula (Xaa-Yaa-Gly)n, where one of the positions Xaa or Yaa is a bulky, non-electron withdrawing proline derivative. By substituting a proline derivative at either the Xaa or Yaa position in the native collagen helix, the stability of the helix is increased due solely to steric effects relative to prior known collagen-related triple helices. Methods are also disclosed for making the novel collagen mimics.
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: September 12, 2017
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Ronald T. Raines, Matthew D. Shoulders, Jonathan A. Hodges
  • Patent number: 9758570
    Abstract: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (I?Ip) and compositions thereof from blood.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: September 12, 2017
    Assignee: ProThera Biologics, Inc.
    Inventors: Yow-Pin Lim, Edward S. Sirya, Peter Brne
  • Patent number: 9758571
    Abstract: There are provided peptide tags derived from bacteriophytochrome (BphP) that is photoreceptor protein of Deinococcus radiodurans, an antibody capable of specifically recognizing the peptide tags, hybridoma cell lines capable of producing the antibody, and uses thereof. The novel peptide tag has advantages in that it has a short length and can remove a non-specific reaction of the conventional c-myc tag and FLAG tag. Therefore, in the case of using the novel peptide tag and antibody thereto, the fusion protein expressed in a recombinant cell can be very effectively detected or purified. In addition, an epitope tagging system including the novel peptide tag and antibody thereto can be applied in various fields such as a determination of an intracellular site, a confirmation of functionality, detection and purification of specific protein, and researches on interaction between proteins.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: September 12, 2017
    Assignees: University—Industry Cooperation Group Of Kyung Hee University, Myongji University Industry and Academia Cooperation Foundation
    Inventors: Seong Hee Bhoo, Tae Ryong Hahn, Tae Lim Kim, Joo Won Suh, Seung Hwan Yang